PHARMACY

Tribenzor well-tolerated among older patients in study

BY Alaric DeArment

PARSIPPANY, N.J. — A drug made by Daiichi-Sankyo was safe and effective in maintaining reductions in blood pressure in older patients, according to a new study presented at the American Society of Hypertension’s 26th annual meeting in New York.

The “TRINITY” study of Tribenzor (olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide) showed the drug was well-tolerated and effective in patients ranging in age from younger than 65 years to older than 65 years, after a year.

“Older patients generally have a more difficult time achieving recommended blood pressure levels and as a result, their hypertension often remains uncontrolled,” University of Alabama medical professor Suzanne Oparil said. “However, this analysis shows that long-term blood-pressure control can be achieved safely and effectively across all studied dosing strengths with a triple combination therapy regardless of age.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Report: States scale back funding to HIV, AIDS medication programs

BY Alaric DeArment

NEW YORK — Several states are cutting funding to programs that provide HIV medications to people who can’t afford them in an effort to reduce spending, according to a published report.

The Washington Post reported that more than 8,300 people are on waiting lists to obtain antiretrovirals and other drugs that treat HIV, AIDS and related conditions. The Post article highlighted particularly large program cuts in Illinois and Georgia, as well as one proposed for Florida.

The programs are designed for patients who can’t afford HIV/AIDS drugs, lack insurance or have limited coverage.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Lilly inks deal with Care Capital, NovaQuest Capital to establish BioCritica

BY Alaric DeArment

INDIANAPOLIS — Drug maker Eli Lilly is partnering with two private investor groups to form a new biotech company based in central Indiana, the company said Monday.

Lilly signed a deal with Care Capital and NovaQuest Capital to establish BioCritica, a privately held biotechnology company that will focus on continued U.S. development and commercialization of the severe sepsis treatment Xigris (drotrecogin alfa [activated]). The new company also will expand its portfolio of critical care medicines for hospitals.

Under a licensing agreement, BioCritica will acquire U.S. development and commercialization rights to Xigris and receive rights to potentially acquire several critical care compounds in preclinical development at Lilly.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES